Elon Musk’s brain implant company, Neuralink, has secured $600 million in funding, placing the company’s valuation at $9 billion prior to the new investment, according to sources familiar with the matter.
Privately executed stock transactions reported that investors valued the startup at approximately $5 billion in 2023. Earlier, the company raised $280 million in a funding round led by Peter Thiel’s Founders Fund.
Neuralink is currently testing its brain implant device, that will assist people with spinal cord injuries. The technology has enabled the first patient to play video games, browse the internet, post on social media, and control a cursor on a laptop using only brain signals.
In April, reports indicated that Neuralink planned to raise about $500 million. Earlier this month, the company’s speech restoration device received the U.S. Food and Drug Administration’s (FDA) “breakthrough” designation, a significant milestone signaling the device’s potential impact.
Elon Musk has ambitious plans for Neuralink’s technology, envisioning it as a tool not only for treating conditions like obesity, autism, depression, and schizophrenia but also for everyday applications such as web browsing and even telepathy. He imagines a future where healthy and disabled individuals can visit local facilities for quick and easy surgical implant procedures.
With its latest funding round and FDA breakthrough designation, Neuralink is rapidly advancing toward transforming how brain-computer interfaces can improve lives. Backed by significant investment and visionary leadership, the company is poised to make major strides in medical technology and reshape the future of human-machine interaction.
